WO2024081739A3 - Covalent compounds and uses thereof - Google Patents

Covalent compounds and uses thereof Download PDF

Info

Publication number
WO2024081739A3
WO2024081739A3 PCT/US2023/076610 US2023076610W WO2024081739A3 WO 2024081739 A3 WO2024081739 A3 WO 2024081739A3 US 2023076610 W US2023076610 W US 2023076610W WO 2024081739 A3 WO2024081739 A3 WO 2024081739A3
Authority
WO
WIPO (PCT)
Prior art keywords
compound
covalent compounds
methods
covalent
targets
Prior art date
Application number
PCT/US2023/076610
Other languages
French (fr)
Other versions
WO2024081739A2 (en
Inventor
Anthony John Iafrate
Liron BAR-PELED
Diane YANG
Brian LIAU
Stefan HARRY
Original Assignee
The General Hospital Corporation
President And Fellows Of Harvard College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The General Hospital Corporation, President And Fellows Of Harvard College filed Critical The General Hospital Corporation
Publication of WO2024081739A2 publication Critical patent/WO2024081739A2/en
Publication of WO2024081739A3 publication Critical patent/WO2024081739A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/34—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
    • C07C233/35—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/36—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/34—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
    • C07C233/35—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/38—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a carbon atom of an acyclic unsaturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/34—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
    • C07C233/42—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
    • C07C233/43—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of a saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/90—Carboxylic acid amides having nitrogen atoms of carboxamide groups further acylated
    • C07C233/91—Carboxylic acid amides having nitrogen atoms of carboxamide groups further acylated with carbon atoms of the carboxamide groups bound to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/78—Halides of sulfonic acids
    • C07C309/79—Halides of sulfonic acids having halosulfonyl groups bound to acyclic carbon atoms
    • C07C309/83—Halides of sulfonic acids having halosulfonyl groups bound to acyclic carbon atoms of a carbon skeleton substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/60—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton with the carbon atom of at least one of the carboxyl groups bound to nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/02—Ortho- or ortho- and peri-condensed systems
    • C07C2603/40—Ortho- or ortho- and peri-condensed systems containing four condensed rings
    • C07C2603/42—Ortho- or ortho- and peri-condensed systems containing four condensed rings containing only six-membered rings
    • C07C2603/50—Pyrenes; Hydrogenated pyrenes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The present document relates to covalent compounds and uses thereof, including methods of targeting or engaging one or more targets with a covalent compound. Also provided herein are methods of treating a disease using such a compound and methods of identifying one or more targets using such a compound.
PCT/US2023/076610 2022-10-11 2023-10-11 Covalent compounds and uses thereof WO2024081739A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202263415279P 2022-10-11 2022-10-11
US63/415,279 2022-10-11
US202363506966P 2023-06-08 2023-06-08
US63/506,966 2023-06-08

Publications (2)

Publication Number Publication Date
WO2024081739A2 WO2024081739A2 (en) 2024-04-18
WO2024081739A3 true WO2024081739A3 (en) 2024-05-16

Family

ID=90670333

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2023/076610 WO2024081739A2 (en) 2022-10-11 2023-10-11 Covalent compounds and uses thereof

Country Status (1)

Country Link
WO (1) WO2024081739A2 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100261639A1 (en) * 2007-05-28 2010-10-14 University Of Manitoba Triazole-based aminoglycoside-peptide conjugates and methods of use
US20170305918A1 (en) * 2015-01-18 2017-10-26 Newave Pharmaceutical Inc. Dual-warhead covalent inhibitors of fgfr-4
US20180369242A1 (en) * 2015-12-15 2018-12-27 Precedo Pharmaceuticals Co., Ltd Novel egfr and alk dual inhibitor

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100261639A1 (en) * 2007-05-28 2010-10-14 University Of Manitoba Triazole-based aminoglycoside-peptide conjugates and methods of use
US20170305918A1 (en) * 2015-01-18 2017-10-26 Newave Pharmaceutical Inc. Dual-warhead covalent inhibitors of fgfr-4
US20180369242A1 (en) * 2015-12-15 2018-12-27 Precedo Pharmaceuticals Co., Ltd Novel egfr and alk dual inhibitor

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHEN XIAOJUAN, LI HUILIANG; LIN QIANMENG; DAI SHUYAN; YUE SITONG; QU LINGZHI; LI MAOYU; GUO MING; WEI HUDIE; LI JUN; JIANG LONGYIN: "Structure-based design of a dual-warhead covalent inhibitor of FGFR4", COMMUNICATIONS CHEMISTRY, SPRINGER NATURE, vol. 5, no. 1, XP093172920, ISSN: 2399-3669, DOI: 10.1038/s42004-022-00657-9 *
DATABASE Compound summary 16 May 2005 (2005-05-16), PUBCHEM: "N-[(3-methoxy-4-phenylmethoxyphenyl)-(prop-2-enoylamino)methyl]prop-2-enamide | C21H22N2O4 ", XP093172923, Database accession no. CID 2526939 *

Also Published As

Publication number Publication date
WO2024081739A2 (en) 2024-04-18

Similar Documents

Publication Publication Date Title
MA32836B1 (en) EXTRACT OF AERIAL PARTS OF OATS HARVESTED BEFORE THE APPEARANCE OF EPIS
MX2018009913A (en) Max binders as myc modulators and uses thereof.
EP4375382A3 (en) Bacterial strains having fungicidal activity, compositions comprising same and use thereof
WO2022159685A3 (en) Sars-cov-2 coronavirus antibodies and uses thereof
WO2022218941A3 (en) Compositions and methods for inhibiting ketohexokinase (khk)
MX2022012110A (en) Class ii, type ii crispr systems.
WO2021226071A3 (en) Detecting pancreatic neuroendocrine tumors
EP1594885B8 (en) Medicament for inhibiting tumour growth
WO2023108110A3 (en) Combination therapy for treating abnormal cell growth
WO2020146700A8 (en) Lipid nanoparticles
WO2023287730A8 (en) Tricyclic compounds
WO2023122260A3 (en) Inhibitors of sars-cov-2
MX2022007628A (en) Combinations.
WO2022204713A3 (en) Antibodies to sars-cov-2
WO2022232016A3 (en) Chimeric receptors targeting adgre2 and/or clec12a and uses thereof
WO2024081739A3 (en) Covalent compounds and uses thereof
WO2023064282A8 (en) Combinations of wee 1 inhibitors and anti-cd47 antibodies.
WO2023107574A3 (en) Lipid-based compositions and methods thereof
MX2023015245A (en) Substituted pyrimidinyl-pyrazoles as cdk2 inhibitors.
CA3199014A1 (en) Combination therapy for the treatment of a liver disease
WO2024077224A3 (en) Novel microbial genotoxins
WO2023122213A8 (en) Targeting gdf15-gfral pathway
WO2023150260A3 (en) Multispecific compounds that target tem8, compositions, and methods
WO2024037633A3 (en) Formulations comprising g-csf and uses thereof
WO2024020564A8 (en) Anti-steap1 antigen-binding molecules and uses thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23878198

Country of ref document: EP

Kind code of ref document: A2